That is an unsatisfying answer if you came here expecting a food list. It is also the honest one, and it changes what you should actually do with an elevated result. The rest of this guide covers each lever, what is worth testing alongside it, and when the number is worth a conversation with a clinician.
Lipoprotein (a) is an LDL-like particle carrying an extra protein, apolipoprotein(a), and research consistently associates higher levels with atherosclerotic cardiovascular disease and aortic valve disease[1]. It is measured from a standard blood draw, reported in either mg/dL or nmol/L, and generally does not require fasting[2]. The two units are not interchangeable, so compare like with like across tests[3]. A typical lab reference range is 0 to 30 mg/dL, and FitScript's optimal range is 0 to 14 mg/dL. Optimal ranges are optimization targets, not diagnostic cut-offs, and reference ranges vary by lab, age and sex. One elevated value describes lifetime risk exposure, not a diagnosis. For the full breakdown of the marker, the assay and what high or low results may reflect, see Lipoprotein (a).
Related: Does Everyone Have Lipoprotein(a)? (What Levels Mean)
Because it is largely written into a single gene. The LPA gene codes for apolipoprotein(a), and a repeated segment within that gene varies in length between people, with shorter variants generally associated with faster production and higher circulating levels[4]. Production happens in the liver, the rate is mostly inherited, and levels tend to settle in childhood and stay broadly stable through adult life[5].
That biology explains the frustration. Most of the familiar cholesterol levers work by increasing how efficiently the liver clears LDL particles from the blood, or by reducing how much cholesterol the body absorbs or makes. Lipoprotein (a) is not primarily a clearance problem. It is a production problem, driven by genotype, and the particle is cleared through pathways that overlap only partly with LDL. So an intervention can cut LDL cholesterol substantially while leaving Lp(a) untouched, which is exactly what reviews of the marker describe[5].
The practical consequence is worth sitting with. If your level is high, it has probably been high since you were a child, and it is high in some of your relatives too. Nothing you did caused it, and no amount of discipline will undo it. What discipline can do is change the environment that number operates in, which is where most of the real risk reduction available to you lives.
Very little, and sometimes in the direction you would not expect. Across the literature, dietary change produces small and inconsistent effects on Lp(a), far smaller than its effects on LDL cholesterol and triglycerides[5]. There is no food, pattern or elimination that reliably brings a genetically high level into range.
Two nuances are worth knowing. Diets low in saturated fat, which lower LDL cholesterol as expected, may slightly raise Lp(a) at the same time. The effect appears modest, and it is not a reason to go back to a high saturated fat diet, because the overall shift in atherogenic particle burden still favours the lower saturated fat pattern. The second nuance runs the other way. Industrial trans fatty acids are associated with higher Lp(a), which is one more reason to keep them out of the diet entirely.
So where does nutrition actually earn its place here? In everything downstream. The same eating pattern that lowers apoB, improves insulin sensitivity, reduces triglycerides and supports healthy blood pressure reduces the risk that an inherited Lp(a) level can express itself. Fibre-rich plants, adequate protein, mostly unsaturated fats, minimal refined starch and alcohol. Think of diet as reducing the number of other things going wrong in the artery wall rather than as a tool aimed at this particular particle.
Not meaningfully, and that is one of the most reliable findings in this area. Endurance training, resistance training and significant weight loss all improve triglycerides, HDL cholesterol, blood pressure, insulin sensitivity and visceral fat, yet Lp(a) typically stays close to where it started[5]. Lean, highly trained people with an inherited high level still have a high level.
This trips people up because every other line on a lipid panel responds to training, so a flat Lp(a) reads as failure. It is not. The marker is simply not responsive to the stimulus. Occasionally very large energy deficits or extreme endurance loads shift it a little in one direction or the other, and those shifts are small, variable and not a strategy.
The argument for training remains overwhelming, it just has to be made on different grounds. Cardiorespiratory fitness and muscle mass are among the strongest modifiable predictors of long-term cardiovascular and all-cause outcomes available, and both act on risk through mechanisms that have nothing to do with this particle. If Lp(a) is elevated, your total risk is a product of many inputs, and fitness improves several of them at once. Train hard, track blood pressure, apoB, body composition and fitness as your feedback signals, and stop expecting this one number to be the scoreboard.
No over-the-counter supplement is established as lowering lipoprotein (a) and improving cardiovascular outcomes. That is the short version, and the detail matters.
Niacin is the one that genuinely reduces Lp(a), and it is also the clearest cautionary tale. Reviews of Lp(a) treatment describe niacin as lowering the marker while large outcome trials of niacin added to statin therapy did not demonstrate added cardiovascular benefit, alongside meaningful tolerability and safety concerns[6]. Lowering a number is not the same as lowering risk, and this is the example that proves it. High-dose niacin behaves like a drug and belongs in a conversation with a licensed provider, not in a self-directed supplement stack.
Omega-3 fatty acids, coenzyme Q10, red yeast rice, L-carnitine, flaxseed and garlic have not been shown to produce a clinically useful reduction in Lp(a). The vitamin C and lysine combination that circulates online rests on a theoretical argument about apolipoprotein(a) binding, and lower levels or fewer events from it are not established.
None of this makes supplements pointless for general health. It makes them the wrong tool for this specific job. If you are taking something marketed for Lp(a), bring it to your clinician so it can be reviewed alongside the rest of your medications.
Statins do not lower lipoprotein (a), and research suggests statin therapy is associated with a modest increase in it[7]. That finding is real, it is reproducible, and it is routinely misread.
Here is the context that matters. The same medicines substantially reduce LDL cholesterol and apoB, and the reduction in atherosclerotic events associated with that effect is one of the best-documented findings in cardiovascular medicine. A small upward drift in Lp(a) sits inside a much larger downward move in total atherogenic particle burden. An elevated Lp(a) result is not a sign that cholesterol-lowering therapy is failing you, and it is not a reason to stop or decline it. Whether lipid-lowering therapy of any kind is appropriate is a decision a licensed provider makes after reviewing your full picture.
What the finding does justify is a conversation. If you take cholesterol-lowering medication and your Lp(a) is high, your clinician may want to look at apoB rather than LDL cholesterol alone as the measure of how well therapy is working, because apoB counts every atherogenic particle including Lp(a). Some people with a high Lp(a) are also candidates for more aggressive targets on the markers that can be moved, precisely because one component of their risk cannot be. That is a clinical judgement, not a self-service adjustment.
Two established approaches reduce lipoprotein (a), and neither is prescribed for that purpose alone.
PCSK9 inhibitors lower Lp(a) by a modest amount alongside their much larger effect on LDL cholesterol, and analyses have explored how much of their cardiovascular benefit might relate to that Lp(a) reduction[8]. The Lp(a) effect is real but partial, and these medicines are used primarily for LDL lowering in people who meet specific clinical criteria. A licensed provider evaluates whether they are appropriate.
Lipoprotein apheresis is the most powerful option currently available. It filters apoB-containing particles, including Lp(a), directly from the blood during a repeated procedure, and it is reserved for selected patients with very high levels and progressive disease despite maximal medical therapy[9]. Access, eligibility criteria and funding vary considerably between health systems, and it is a specialist-led decision.
A few other therapies shift the number incidentally. None of them is used as an Lp(a) treatment in its own right, and each carries their own risk and benefit considerations that a licensed provider weighs individually. This guide gives no doses, schedules or administration guidance for any of these, because that is a prescribing decision made by a clinician who has examined you.
For the first time, therapies designed specifically to reduce apolipoprotein(a) production are in late-stage testing. Reviews of lipoprotein (a) as a pharmacological target describe antisense oligonucleotides and small interfering RNA agents that switch down hepatic apo(a) synthesis, producing large reductions in circulating levels in trials[10]. A different approach uses an oral small molecule, muvalaplin, which interferes with the assembly of the Lp(a) particle itself and reduced measured levels in a randomized trial[11].
The crucial caveat is that lowering the marker and lowering events are separate questions. Whether reducing Lp(a) reduces heart attacks, strokes and aortic valve disease is not yet known, and until that is answered, the benefit is a well-reasoned hypothesis rather than an established fact. The niacin story is the reason to hold that line carefully.
What this means for you in 2026 is modest but genuine. Knowing your level now puts you in a position to act quickly if and when these agents become clinically available, and to ask early about how access currently works. If that interests you, raise it with your clinician, who can assess what is suitable and where it is available. Do not attempt to source anything in this category outside of regulated care.
Reduce everything else, aggressively and early. Lipoprotein (a) does not act alone. Its contribution to atherosclerotic risk is amplified by the other factors present in the same artery wall, and reviews of the marker frame it as one component of total risk rather than a standalone verdict[12]. The same elevated level carries a very different practical meaning in a non-smoker with normal blood pressure and a low apoB than in someone with untreated hypertension, insulin resistance and a high particle count.
That gives you a concrete agenda. Get apoB as low as your clinical situation justifies, since it measures the total number of atherogenic particles rather than the cholesterol inside them. Treat blood pressure properly, because pressure and particles interact mechanically at the vessel wall. Do not smoke or vape nicotine. Address insulin resistance through training, body composition and sleep. Keep inflammation in view.
Two further steps are worth raising with a clinician. The first is family screening, because Lp(a) is inherited and first-degree relatives have a meaningfully higher chance of carrying an elevated level themselves. The second is imaging. In some people with a high level and uncertain overall risk, a clinician may consider coronary artery calcium scoring or carotid imaging to see whether disease is actually present, which often clarifies how intensively to treat the modifiable factors.
Several medical conditions shift lipoprotein (a) independently of genetics, which matters because they can make a one-off reading misleading. Kidney disease raises it, with nephrotic syndrome producing some of the largest increases seen outside of genetic extremes. Untreated hypothyroidism is associated with higher levels, and treating the thyroid can bring them down, while hyperthyroidism tends to push them the other way.
Lp(a) also behaves partly as an acute phase reactant, meaning levels can rise during infection, after surgery, during a flare of an inflammatory condition or in the weeks after a heart attack. Testing during any of those windows can produce a number that does not represent your stable baseline. Pregnancy raises levels, and they fall again afterwards. In women, levels tend to increase around and after menopause, which is one of the few reasons a stable adult value genuinely changes over time.
Growth hormone and androgen exposure can alter the number as well, in either direction depending on the agent.
The practical rule is simple. Test when you are clinically stable and well, not in the middle of an illness or immediately after a major event. If a result is unexpectedly high and one of these situations applies, the sensible next step is a repeat test once things have settled rather than a decision based on the first number. Interpret the trend alongside kidney and thyroid markers.
The table below summarises where each commonly discussed approach currently stands. It is a map of where effort is and is not rewarded, not a treatment recommendation.
| Approach | What research suggests about Lp(a) | Practical note |
|---|---|---|
| Low saturated fat diet | Little effect, may raise it slightly while lowering LDL | Still worth doing for apoB and overall risk |
| Low carbohydrate or ketogenic diet | No consistent reduction | Judge it on triglycerides, weight and apoB instead |
| Weight loss | Generally no meaningful change | Improves blood pressure, glucose and triglycerides |
| Aerobic or resistance training | Generally no meaningful change | Fitness remains a major independent risk modifier |
| Omega-3, CoQ10, garlic, flaxseed | No convincing reduction | Reasonable for other purposes, not for this |
| Vitamin C with lysine | Benefit not established | Theory-driven, widely promoted online |
| Common cholesterol-lowering medicines | No reduction, may rise modestly | Still central to lowering LDL and apoB, provider decides |
| Another class of cholesterol-lowering medicine | Modest reduction alongside large LDL lowering | Prescribed on clinical criteria by a licensed provider |
| Lipoprotein apheresis | Largest available reduction | Specialist-led, for selected high-risk patients |
| apo(a)-targeted drugs | Large reductions in measured levels | Outcome data pending, access currently limited |
The markers that tell you how much your Lp(a) actually matters. On its own, the value is a risk multiplier without a thing to multiply, so it should be read next to the rest of your atherogenic picture[12].
Apolipoprotein B is the single most useful companion, because it counts every atherogenic particle in circulation, including Lp(a) particles, and it is the lever you can actually pull. LDL cholesterol gives the conventional reference point most clinicians still work from, and comparing it with apoB shows whether your particles are cholesterol-rich or cholesterol-poor. A high-sensitivity C-reactive protein adds the inflammatory dimension, which is relevant both because inflammation contributes to plaque behaviour and because it can temporarily inflate an Lp(a) reading. Homocysteine is worth having in view as an additional vascular marker that responds to B vitamin status and kidney function.
Beyond lipids, a full picture usually includes fasting glucose and HbA1c, triglycerides, kidney function, thyroid markers and blood pressure. FitScript tests 150+ biomarkers per year and Atlas, its AI health advisor, interprets how the results relate to each other rather than one line at a time. The point of the wider panel is not more data for its own sake, it is working out which of your modifiable risks deserves attention first.
For most adults, once is genuinely informative, because the level is largely genetic and stays broadly stable through life. Professional guidance has moved toward measuring lipoprotein (a) at least once in adult life so that the information is on record and can inform decisions about the risk factors that can be changed[2].
Repeat testing earns its place in specific situations. If the first sample was taken during an acute illness, after surgery, during pregnancy or soon after a cardiovascular event, a repeat once you are stable gives a truer baseline. If kidney function or thyroid status has changed, or been treated, the number may have moved with it. Women may see a genuine shift around menopause. And if a therapy that affects Lp(a) is started under medical supervision, your clinician will decide what monitoring makes sense.
One more practical reason to retest is unit confusion. Results in mg/dL and nmol/L are not interchangeable, and assays differ in how they handle the variable size of apolipoprotein(a), so two results from different laboratories can look like a change when nothing has changed[3]. Where possible, track the number using the same laboratory and the same unit, and note which unit a result is reported in before comparing anything.
Whenever the result is above the standard reference range, and sooner if anything else in your history points the same way. A suboptimal or elevated lipoprotein (a) is not a diagnosis and it does not mean disease is present, but it does change the calculation about how intensively your other risk factors deserve to be managed, and that calculation belongs to a clinician who knows your full history.
Bring the conversation forward if you have a family history of heart attack, stroke or aortic valve disease before the age of about 60, if a close relative has a known high Lp(a), if you have already had a cardiovascular event, if you have been told you have aortic valve narrowing, or if disease appears to be progressing despite a well-controlled LDL cholesterol. Kidney disease, familial hypercholesterolaemia and a high apoB alongside a high Lp(a) all make the discussion more urgent. Any new chest pain, breathlessness on exertion, or neurological symptoms are worth discussing with a clinician promptly, independently of any lab value.
What to ask for is straightforward. Clarify your total cardiovascular risk rather than this one marker, agree on an apoB target, review blood pressure, and ask whether first-degree relatives should be tested. Discuss your results and any treatment with a clinician or licensed provider before acting on them. This page is educational information and not medical advice.
If you want to go deeper on the individual markers mentioned here, the detail pages for apolipoprotein b, ldl cholesterol, c reactive protein and homocysteine each explain what the test measures and how results are interpreted, and the Heart Health panel shows how these markers are usually grouped on a single draw.
Lifestyle change does very little, because the level is mostly genetic. Established reduction comes from medical options such as PCSK9 inhibitors or lipoprotein apheresis, which a licensed provider decides on, with apo(a)-targeted drugs still in trials. Meanwhile, the highest-value action is lowering apoB, blood pressure, smoking and insulin resistance.
Not meaningfully. Dietary change produces small and inconsistent effects on lipoprotein (a), and low saturated fat diets may raise it slightly while lowering LDL. Diet still matters enormously for apoB, triglycerides and blood pressure, which is where nutrition reduces your overall cardiovascular risk.
Generally not. Aerobic training, resistance training and weight loss improve triglycerides, blood pressure, insulin sensitivity and fitness, yet lipoprotein (a) usually stays close to where it started. Highly trained people with an inherited high level still have one. Train for the risk factors that do respond, and track apoB instead.
It is worth taking seriously without treating it as a diagnosis. An elevated level is associated with higher atherosclerotic and aortic valve risk across a lifetime, but it acts alongside other factors. Discuss the result with a clinician, who can assess your total risk and whether relatives should be tested.
For most adults a single measurement is largely sufficient, since levels are genetically set and stable. Repeat testing makes sense if the first sample was taken during illness, pregnancy or soon after a cardiovascular event, or if kidney function, thyroid status or menopausal status has changed. Your clinician decides.
They measure different things. One reports mass and the other reports particle concentration, and the variable size of apolipoprotein(a) means there is no simple universal conversion between them. Compare results in the same unit from the same laboratory where possible, and check which unit appears on each report before assuming a change.
Several apo(a)-targeted therapies, including injectable RNA-based agents and an oral small molecule, lower the measured level substantially, but benefit on cardiovascular events remains unproven. Access is currently mainly through clinical trials, and a licensed provider evaluates whether participation is suitable.